Platelet-activating effect low-density lipoprotein reversal isradipine effect calcium antagonist isradipine platelet aggregation induced ex vivo serotonin low-density lipoprotein LDL nonsmoking patients essential hypertension Platelet aggregation four-week placebo period weeks treatment isradipine serotonin-induced LDL serotonin-induced platelet aggregation weeks isradipine treatment placebo effect LDL serotonin-induced aggregation significant placebo active treatment isradipine decrease platelet aggregation LDL serotonin weeks isradipine treatment amplification serotonin-induced aggregation LDL conclusion treatment isradipine restores impaired platelet response LDL hypertensive patients inhibition response cellular mechanism thrombovascular protection 